Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 1336967,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/1336967/?format=api",
    "text_counter": 179,
    "type": "speech",
    "speaker_name": "Dagoretti North, ODM",
    "speaker_title": "Hon. Beatrice Elachi",
    "speaker": null,
    "content": "in drugs. Are these drugs, especially antibiotics, better for Kenyans or are we just worsening the situation of this patient? These are very critical things that we need to look at. Today, if you take Augmentin for a week, in two to three weeks, you find yourself again with the same attack that you had. Does it mean that this drug is becoming another menace? For me, there are two things we have to look at. As we look at this, there is need for the Departmental Committee on Health to walk around and look at that H.pylori kit which has been changed for a new one. They are saying this is better than the other one, but did they sensitise Kenyans? How does this one become better than the other one? How does a Kenyan in the rural area understand that this is a better kit than the other one? I have used those two drugs that I have talked about. I have used the new H.pylori kit and in three months, I went back to the same challenges that I was facing and this is a kit that you buy at Ksh15,000. There is need to be very serious in terms of regulations on how we set up chemists, but more importantly, how we deal with drugs today in our country. All the pharmaceutical companies that we have must tell us where they do their public participation."
}